Summary of opinion: Rinvoq, 23/07/2026 Positive
Submitted by Anonymous (not verified) on 24 July 2026 - 11:00
Summary of opinion: Rinvoq, 23/07/2026 Positive
Summary of opinion: Repatha, 23/07/2026 Positive
Submitted by Anonymous (not verified) on 24 July 2026 - 11:00
Summary of opinion: Repatha, 23/07/2026 Positive
Summary of opinion: Trixeo Aerosphere, 23/07/2026 Positive
Submitted by Anonymous (not verified) on 24 July 2026 - 11:00
Summary of opinion: Trixeo Aerosphere, 23/07/2026 Positive
Summary of opinion: Piqray, 23/07/2026 Positive
Submitted by Anonymous (not verified) on 24 July 2026 - 11:00
Summary of opinion: Piqray, 23/07/2026 Positive
Summary of opinion: Riltrava Aerosphere, 23/07/2026 Positive
Submitted by Anonymous (not verified) on 24 July 2026 - 11:00
Summary of opinion: Riltrava Aerosphere, 23/07/2026 Positive
First oral medicine targeting interleukin-23 receptor recommended for plaque psoriasis
Submitted by Anonymous (not verified) on 24 July 2026 - 11:00
First oral medicine targeting interleukin-23 receptor recommended for plaque psoriasis
New treatment option for neovascular age-related macular degeneration
Submitted by Anonymous (not verified) on 24 July 2026 - 11:00
New treatment option for neovascular age-related macular degeneration
Withdrawn application: Imfinzi, 24/06/2026
Submitted by Anonymous (not verified) on 24 July 2026 - 11:00
Withdrawn application: Imfinzi, 24/06/2026
Summary of opinion: Enhertu, 23/07/2026 Positive
Submitted by Anonymous (not verified) on 24 July 2026 - 11:00
Summary of opinion: Enhertu, 23/07/2026 Positive
Human medicines European public assessment report (EPAR): Nezglyal, leriglitazone, Status: Opinion
Submitted by Anonymous (not verified) on 24 July 2026 - 11:00
Human medicines European public assessment report (EPAR): Nezglyal, leriglitazone, Status: Opinion